Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar User Fees Would Be Same As BLAs, Only Earlier

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's proposed biosimilar product development fee would be charged upon IND submission, but subtracted from marketing application fee.

Related Content

Biosimilar User Fee Agreement Reached, But Will Require Appropriations Boost
Biosimilar Product Development Meetings With FDA To Be Flexible Under User Fee Program
Biosimilar User Fee Negotiations Hit Snag With GPhA Gambit For Lower Fees
Reactivation Fee Is Proposed For Biosimilar INDs Placed On Hold
How Should FDA Collect The Biosimilar Product Development Fee?
Biosimilar User Fee Negotiations Under Way; Timetable Compressed
Biosimilar Product Development Fee Should Be Temporary, Trade Groups Say
Biosimilar Manufacturing Issues Should Be Focus Of User Fee Program, Firms Say
Biosimilars: FDA Trying Group-Think Negotiating Strategy For User Fee
FDA Expects Sharp Drop In Drug Applications This Year





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts